BPTH — Bio Path Holdings Share News
0.000.00%
Last trade - 00:00Brief: Bio-Path Holdings Presents BP1003 Data At 2022 American Association For Cancer Research Annual Meeting
Bio Path Holdings Inc reports results for the quarter ended in December - Earnings Summary
Bio Path Holdings Inc expected to post a loss of 32 cents a share - Earnings Preview
Bio Path Holdings Inc expected to post a loss of 32 cents a share - Earnings Preview
Brief: Bio Path Holdings - On Feb 15, Co Notified Nasdaq That Due Solely To Director Resignation, Co Is Not In Compliance With Continued Listing Requirements
Brief: Bio Path Holdings Reports Q3 Loss Per Share $0.29
Bio Path Holdings Inc reports results for the quarter ended in September - Earnings Summary
Bio Path Holdings Inc expected to post a loss of 33 cents a share - Earnings Preview
Brief: Bio-Path Announces Clearance Of IND Application For Phase 1/1B Clinical Trial Of Prexigebersen-A In Solid Tumors
Brief: Bio-Path Holdings Announces Clearance Of Investigational New Drug Application For Bp1002 In Refractory/Relapsed Acute Myeloid Leukemia Patients
Bio-Path jumps on FDA nod for cancer therapy clinical trial
Brief: Bio-Path Holdings Reports Second Quarter 2021 Financial Results
Bio Path Holdings Inc expected to post a loss of 39 cents a share - Earnings Preview
Brief: Bio-Path Granted Key Mechanism Of Action U.S. Patent For Bp1003
Bio Path Holdings Inc reports results for the quarter ended in March - Earnings Summary
Brief: Bio-Path Holdings Reports Q1 Loss Per Share Of $0.43
Bio Path Holdings Inc expected to post a loss of 49 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Alphabet Inc, AMC Entertainment, oil stocks, cruise stocks
U.S. STOCKS ON THE MOVE-AeroCentury, Molecular Templates, Tesla Inc and Xcel Brands